http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180016076-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0624908c7150e45bdd907be4f162057e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-323 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2016-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e0971cbed155d5bd719316e9ea54c9d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebc4fa8c0f94b1603710b88614c5f325 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b13e133f10e5d0504a592df05a7ba589 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_760269a9ca196c97cc431951e50794e8 |
| publicationDate | 2018-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20180016076-A |
| titleOfInvention | Composition comprising PTP4A1 protein or polynucleotide encoding the PTP4A1 for the prevention or treatment of vascular-inflammatory disease |
| abstract | The present invention relates to a pharmaceutical composition for the prevention or treatment of vascular diseases, comprising as an active ingredient a PTP4A1 (protein tyrosine phosphatase type IV A1) protein or a polynucleotide encoding the same, wherein specifically the PTP4A1 protein is IL-1β, TNF- LPS inhibited the expression of the cell adhesion proteins ICAM-1 and VCAM-1 in vascular endothelial cells induced by inflammatory responses and inhibited the adhesion of immune cells to the surface of vascular endothelial cells that induced inflammation with IL-1β or TNF-α And that the expression of the cell adhesion proteins ICAM-1 and VCAM-1 in the arterial blood vessels and pulmonary blood vessels caused by TNF-α was markedly suppressed in the mouse (TG) specifically overexpressed in the vascular endothelial cells as compared with the control (WT) , And the expression of inflammatory cytokines and inflammatory cytokines in ApoE-deficient mouse atherosclerotic lesions overexpressing PTP4A1 after high fat diet decreased compared to the control group, The effect of improving the sex was shown. In addition, inhibition of the expression of the cell adhesion molecule suppresses the expression of ICAM-1 and VCAM-1 by inhibiting NF-κB activity by increasing the expression of A20 protein by increasing the expression of TRAF2 and RIP1 protein by PTP4A1 , The PTP4A1 protein of the present invention and the polynucleotide encoding the PTP4A1 protein can be usefully used as a pharmaceutical composition for the prevention or treatment of vascular inflammation diseases. |
| priorityDate | 2016-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 458.